Disease control is not accomplished in individuals with severe asthma, resulting in long-term morbidity and increased risk of exacerbations. The introduction of biologics has opened up new avenues of treatment for many people suffering from severe asthma. For clinical usage, four mAb biologics have been approved: omalizumab (anti-IgE) and three anti eosinophilic treatments (mepolizumab, reslizumab, and benralizumab). These four biologics target components of the type 2 inflammatory system, as shown by biomarkers: peripheral blood eosinophils and exhaled nitric oxide. Biologics have been shown to decrease asthma exacerbations in patients with severe asthma. Lung function has also improved as a result of the anti eosinophilic biologics. These biochemicals have a high safety profile.

Biologics have proved to be a successful strategy to disease management for individuals with severe asthma and biomarkers suggesting a type 2 inflammatory pathway, and are an acceptable next step therapy.

Reference: https://journals.lww.com/co-allergy/Abstract/2018/12000/Biological_treatments_for_severe_asthma__where_do.10.aspx